drugset / Trial / NCT01836861

IPI-145 ADME and Absolute Bioavailability Study

NCT01836861

Phase 1 Completed 6 enrolled SecuraBio
NaSingle-groupOpen-labelBasic science

Summary

This is an open-label, 2-period, absorption, distribution, metabolism and excretion (ADME) and absolute bioavailability study in 6 healthy adult male subjects.

Timeline

Start
2013-03
Primary completion
2013-04
Completion
2013-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Duvelisib Small molecule 2.8 ug Intravenous
Subject Duvelisib Small molecule 25 mg Intravenous

Indications

No indication recorded.